GlaxoSmithKline

Dupixent, a drug by Sanofi and Regeneron, has received FDA approval for treating COPD, becoming the first biologic therapy for the condition. The drug targets type 2 inflammation driven by eosinophils, showing significant reductions in COPD exacerbations in Phase 3 trials. Dupixent has previously been approved for dermatitis and asthma, contributing to €10.7 billion in sales in 2023.

Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.

Immunotherapies are crucial for multiple myeloma (MM) but face resistance and relapse. Proteasome inhibitors (PIs) and targeted therapies like BCL2 and BRAF/MEK inhibitors offer alternatives. Clonal evolution and subclonal mutations drive disease progression. Combination therapies, including melphalan, increase mutational load. Resistance to lenalidomide and anti-CD38 antibodies is common, but combinations like carfilzomib, daratumumab, and dexamethasone improve progression-free survival (PFS). BCMA-targeted antibody-drug conjugates (ADCs) show promise. Targeted inhibitors for BCL2, BRAF/MEK, and NSD2 benefit refractory patients. Despite clinical promise, access to these therapies is limited, highlighting the need for cost-effective treatments and innovative approaches.

FDA approves Regeneron and Sanofi's Dupixent for COPD, making it the first biologic treatment for the condition. Dupixent, an interleukin-4 receptor alpha antagonist, showed reduced exacerbations and improved lung function in Phase III studies. The approval follows failures of GSK's Nucala and AstraZeneca's Fasenra in COPD trials.

Sanofi and Regeneron's Dupixent is the first biologic approved in the U.S. for COPD, potentially benefiting 300,000 adults with poorly controlled disease. Dupixent showed a 30-34% reduction in COPD exacerbations in Phase III studies and is consistent with existing safety profiles. The approval adds to Dupixent's list of FDA-approved indications, including asthma and eczema, with anticipated sales of $3.5 billion from the COPD approval. Competitors like GSK, AstraZeneca, and Amgen are also developing treatments for COPD.

Sanofi's Dupixent approved by US FDA for COPD, following EU approval, marking a decade's first new treatment approach for the disease. The drug, co-developed with Regeneron, is expected to generate €21 billion annually by 2030 before facing patent expirations.

FDA approves Dupixent for COPD, making it the first biologic medicine for the condition in the U.S. This expansion is expected to boost sales, which reached almost $12 billion globally last year. Dupixent targets Type 2 inflammation in a subset of COPD patients, showing reduced exacerbations and improved lung function in trials. European regulators approved Dupixent for COPD in July, but U.S. approval required additional efficacy data. The approval comes as Regeneron faces market value loss due to a court case, increasing pressure on its pipeline.

Momelotinib, a JAK inhibitor approved by the FDA in September 2023 for treating myelofibrosis, was developed by Andrew Wilks and Christopher Burns. Their journey included Wilks' discovery of JAK kinases and the drug's path through various companies before GSK's acquisition and commercialization.

Breast cancer treatment market employs various drugs, including chemotherapy, hormone therapies, targeted therapies, and immunotherapy. Market growth is driven by increased incidence, research advancements, early detection awareness, personalized medicine, and new drug classes. The market is projected to reach USD 49.2 billion by 2032, with major companies like Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sun Pharmaceutical, Pfizer, Teva Pharmaceutical, and AbbVie leading in innovation and geographical expansion.

A new drug, MED6-189, targets both the apicoplast and vesicular trafficking pathways in drug-sensitive and resistant strains of _Plasmodium falciparum_, preventing resistance development and showing efficacy in humanized mouse models and against other zoonotic Plasmodium parasites.